ETCHX Performance — Eventide Healthcare & Life Sciences Fund, Class C
Data updated: 2026-09-11
ETCHX returned +11.66% year to date and +70.02% over one year to Jun 2026. Annualised returns are +14.63% over 3 years and +5.70% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $151, against $138 for the category, and to $170 over one year, against $137. Volatility over the past three years was 24.52% a year. In the 12 months to Jun 2026 the fund lost a net $140.3M, and assets reached $1.79B.
ETCHX Growth of $100
What $100 invested in Eventide Healthcare & Life Sciences Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | ETCHX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $170 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $151 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $132 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $179 | $182 |
ETCHX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +11.66% |
| 1 year | +70.02% |
| 3 years (annualised) | +14.63% |
| 5 years (annualised) | +5.70% |
ETCHX Annual Returns
Calendar-year total returns of Eventide Healthcare & Life Sciences Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +11.66% |
| 2025 | +55.14% |
| 2024 | −11.02% |
| 2023 | +9.90% |
| 2022 | −20.42% |
| 2021 | −17.42% |
| 2020 | +35.68% |
| 2019 (Jul–Dec) | +18.26% |
ETCHX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −2.0% | +0.6% | −3.6% | +5.1% | 0.0% | +11.8% | — | — | — | — | — | — |
| 2025 | +7.8% | −4.7% | −9.7% | +3.2% | −1.2% | +7.8% | +4.8% | +10.2% | +5.0% | +13.1% | +13.2% | −1.9% |
| 2024 | −2.6% | +7.7% | −0.3% | −12.4% | +0.5% | −0.3% | +8.4% | +0.7% | −2.3% | −1.2% | +1.9% | −9.6% |
| 2023 | +6.2% | −2.3% | −5.5% | +7.1% | +4.0% | +3.0% | +0.1% | −6.5% | −5.9% | −9.4% | +4.0% | +17.6% |
| 2022 | −18.6% | −3.8% | −2.2% | −15.9% | −3.7% | +4.8% | +7.8% | +9.6% | −3.9% | +1.8% | +1.1% | +4.8% |
| 2021 | −4.6% | +3.8% | −7.0% | −0.9% | −7.9% | +0.3% | −5.1% | +10.0% | −0.4% | +1.0% | −9.2% | +2.6% |
| 2020 | −5.3% | −7.0% | −13.5% | +16.5% | +15.5% | +2.1% | −6.4% | +7.3% | +1.5% | +8.5% | +12.2% | +4.4% |
| 2019 | — | — | — | — | — | — | −1.7% | −8.9% | −9.6% | +8.2% | +23.6% | +9.2% |
ETCHX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 24.52%
- 3-year Sharpe ratio: 0.41 (vs 4.5% risk-free rate)
- Best month: +17.65% (Dec 2023)
- Worst month: −12.44% (Apr 2024)
ETCHX Fund Flows
Monthly money in and out of Eventide Healthcare & Life Sciences Fund, from SEC Form N-PORT.
- 12-month net flow: −$140.3M
- 12-month gross sales (incl. reinvestments): $532.7M
- Sales ÷ redemptions: 0.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $61.7M | $78.0M | −$16.3M |
| May 2026 | $19.4M | $48.8M | −$29.4M |
| Apr 2026 | $21.4M | $45.6M | −$24.3M |
| Mar 2026 | $77.6M | $87.1M | −$9.5M |
| Feb 2026 | $32.9M | $26.7M | $6.2M |
| Jan 2026 | $26.2M | $44.0M | −$17.8M |
| Dec 2025 | $114.2M | $117.1M | −$2.9M |
| Nov 2025 | $29.4M | $37.0M | −$7.6M |
| Oct 2025 | $36.3M | $30.5M | $5.8M |
| Sep 2025 | $20.6M | $36.0M | −$15.4M |
| Aug 2025 | $74.7M | $86.8M | −$12.1M |
| Jul 2025 | $18.2M | $35.3M | −$17.1M |
ETCHX Assets Under Management
Net assets of Eventide Healthcare & Life Sciences Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $1.79B |
| 2026-03-31 | $1.59B |
| 2025-12-31 | $1.69B |
| 2025-09-30 | $1.35B |
| 2025-06-30 | $1.15B |
| 2025-03-31 | $1.12B |
| 2024-12-31 | $1.29B |
| 2024-09-30 | $1.49B |
| 2024-06-30 | $1.44B |
| 2024-03-31 | $1.72B |
| 2023-12-31 | $1.67B |
| 2023-09-30 | $1.56B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.